Coherus Oncology, Inc. (CHRS) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-186.03M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 1.41× | Operating cash flow / net income. Period ending 2026-06-30. $-186.03M ÷ $-132.13M ≈ 1.41× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -186.03M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -132.13M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-186.03M | (m) | (m) | (m) | (m) | $-132.13M | (m) | (m) | (m) | 1.41× |
| 2026-03-31 | (m) | (m) | $-170.57M | (m) | (m) | (m) | (m) | $186.27M | (m) | (m) | (m) | -0.92× |
| 2025-12-31 | (m) | (m) | $-138.51M | (m) | (m) | (m) | (m) | $168.02M | (m) | (m) | (m) | -0.82× |
| 2025-09-30 | (m) | (m) | $-90.19M | (m) | (m) | (m) | (m) | $154.97M | (m) | (m) | (m) | -0.58× |
| 2025-06-30 | (m) | (m) | $-105.87M | (m) | (m) | (m) | (m) | $179.75M | (m) | (m) | (m) | -0.59× |
| 2025-03-31 | (m) | (m) | $500.00K | (m) | (m) | (m) | (m) | $-130.94M | (m) | (m) | (m) | -0.00× |
| 2024-12-31 | (m) | (m) | $-20.44M | (m) | (m) | (m) | (m) | $28.51M | (m) | (m) | (m) | -0.72× |
| 2024-09-30 | (m) | (m) | $-61.98M | (m) | (m) | (m) | (m) | $-450.00K | (m) | (m) | (m) | 137.74× |
| 2024-06-30 | (m) | (m) | $-54.27M | (m) | (m) | (m) | (m) | $-29.34M | (m) | (m) | (m) | 1.85× |
| 2024-03-31 | (m) | (m) | $-152.92M | (m) | (m) | (m) | (m) | $-59.29M | (m) | (m) | (m) | 2.58× |
| 2023-12-31 | $-175.17M | (m) | $-174.88M | $286.00K | (m) | (m) | (m) | $-237.89M | (m) | (m) | (m) | 0.74× |
| 2023-09-30 | $-262.24M | (m) | $-261.90M | $339.00K | (m) | (m) | (m) | $-217.11M | (m) | (m) | (m) | 1.21× |
| 2023-06-30 | $-245.49M | (m) | $-244.69M | $796.00K | (m) | (m) | (m) | $-264.12M | (m) | (m) | (m) | 0.93× |
| 2023-03-31 | $-257.39M | (m) | $-255.81M | $1.58M | (m) | (m) | (m) | $-271.40M | (m) | (m) | (m) | 0.94× |
| 2022-12-31 | $-243.16M | (m) | $-241.12M | $2.04M | (m) | (m) | (m) | $-291.75M | (m) | (m) | (m) | 0.83× |
| 2022-09-30 | $-195.91M | (m) | $-193.49M | $2.42M | (m) | (m) | (m) | $-278.61M | (m) | (m) | (m) | 0.69× |
| 2022-06-30 | $-144.92M | (m) | $-142.69M | $2.22M | (m) | (m) | (m) | $-230.49M | (m) | (m) | (m) | 0.62× |
| 2022-03-31 | $-94.60M | (m) | $-92.84M | $1.76M | (m) | (m) | (m) | $-210.24M | (m) | (m) | (m) | 0.44× |
| 2021-12-31 | $-38.72M | (m) | $-37.43M | $1.29M | (m) | (m) | (m) | $-287.10M | (m) | (m) | (m) | 0.13× |
| 2021-09-30 | $46.24M | (m) | $48.01M | $1.77M | (m) | (m) | (m) | $-231.67M | (m) | (m) | (m) | -0.21× |
| 2021-06-30 | $78.03M | (m) | $81.66M | $3.62M | (m) | (m) | (m) | $-165.21M | (m) | (m) | (m) | -0.49× |
| 2021-03-31 | $136.44M | (m) | $142.03M | $5.59M | (m) | (m) | (m) | $-76.28M | (m) | (m) | (m) | -1.86× |
| 2020-12-31 | $146.91M | (m) | $154.15M | $7.23M | (m) | (m) | (m) | $132.24M | (m) | (m) | (m) | 1.17× |
| 2020-09-30 | $132.06M | (m) | $138.73M | $6.67M | (m) | (m) | (m) | $161.76M | (m) | (m) | (m) | 0.86× |
| 2020-06-30 | $140.86M | (m) | $146.33M | $5.47M | (m) | (m) | (m) | $180.87M | (m) | (m) | (m) | 0.81× |
| 2020-03-31 | $95.55M | (m) | $98.81M | $3.27M | (m) | (m) | (m) | $145.41M | (m) | (m) | (m) | 0.68× |
| 2019-12-31 | $26.53M | (m) | $28.36M | $1.82M | (m) | $356.07M | (m) | $89.83M | (m) | (m) | 7.45% | 0.32× |
| 2019-09-30 | $-38.37M | (m) | $-36.72M | $1.65M | (m) | (m) | (m) | $-11.99M | (m) | (m) | (m) | 3.06× |
| 2019-06-30 | $-135.68M | (m) | $-134.46M | $1.22M | (m) | (m) | (m) | $-117.84M | (m) | (m) | (m) | 1.14× |
| 2019-03-31 | $-183.71M | (m) | $-182.66M | $1.04M | (m) | (m) | (m) | $-185.05M | (m) | (m) | (m) | 0.99× |
| 2018-12-31 | $-160.06M | (m) | $-159.27M | $789.00K | (m) | $0.00 | (m) | $-209.34M | (m) | (m) | (m) | 0.76× |
| 2018-09-30 | $-142.51M | (m) | $-141.82M | $684.00K | (m) | (m) | (m) | $-195.81M | (m) | (m) | (m) | 0.72× |
| 2018-06-30 | $-142.56M | (m) | $-140.55M | $2.01M | (m) | (m) | (m) | $-195.99M | (m) | (m) | (m) | 0.72× |
| 2018-03-31 | $-163.56M | (m) | $-160.59M | $2.96M | (m) | (m) | (m) | $-207.69M | (m) | (m) | (m) | 0.77× |
| 2017-12-31 | $-204.86M | (m) | $-200.29M | $4.57M | (m) | $1.56M | (m) | $-238.17M | (m) | (m) | -13165.75% | 0.84× |
| 2017-09-30 | $-265.29M | (m) | $-257.26M | $8.03M | (m) | $2.40M | (m) | $-265.02M | (m) | (m) | -11053.58% | 0.97× |
| 2017-06-30 | $-284.41M | (m) | $-277.69M | $6.72M | (m) | $165.24M | (m) | $-122.10M | (m) | (m) | -172.12% | 2.27× |
| 2017-03-31 | $-255.56M | (m) | $-249.51M | $6.06M | (m) | $177.91M | (m) | $-136.73M | (m) | (m) | -143.65% | 1.82× |
| 2016-12-31 | $-259.06M | (m) | $-252.54M | $6.51M | (m) | $190.11M | (m) | $-127.34M | (m) | (m) | -136.27% | 1.98× |
| 2016-09-30 | $-164.48M | (m) | $-160.09M | $4.39M | (m) | (m) | (m) | $-103.81M | (m) | (m) | (m) | 1.54× |
| 2016-06-30 | $-164.09M | (m) | $-157.79M | $6.29M | (m) | $43.79M | (m) | $-259.08M | (m) | (m) | -374.69% | 0.61× |
| 2016-03-31 | $-158.24M | (m) | $-151.24M | $7.00M | (m) | $36.59M | (m) | $-247.92M | (m) | (m) | -432.48% | 0.61× |
| 2015-12-31 | $-114.15M | (m) | $-107.99M | $6.16M | (m) | $30.04M | (m) | $-223.26M | (m) | (m) | -379.99% | 0.48× |
| 2015-09-30 | $-152.05M | (m) | $-146.84M | $5.21M | (m) | (m) | (m) | $-200.00M | (m) | (m) | (m) | 0.73× |
| 2015-06-30 | $-95.97M | (m) | $-92.36M | $3.62M | (m) | (m) | (m) | $-136.54M | (m) | (m) | (m) | 0.68× |
| 2015-03-31 | $-75.64M | (m) | $-71.73M | $3.90M | (m) | (m) | (m) | $-102.69M | (m) | (m) | (m) | 0.70× |
| 2014-12-31 | $-26.78M | (m) | $-23.93M | $2.85M | (m) | $31.11M | (m) | $-87.13M | (m) | (m) | -86.08% | 0.27× |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | $10.30M | (m) | $-86.19M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | $5.84M | (m) | $-69.94M | (m) | (m) | (m) | (m) |
| 2013-12-31 | $15.05M | (m) | $15.42M | $373.00K | (m) | $2.75M | (m) | $-53.63M | (m) | (m) | 547.07% | -0.29× |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $-20.03M | (m) | $-18.25M | $1.78M | (m) | $1.90M | (m) | $-33.02M | (m) | (m) | -1054.98% | 0.55× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |